GRI Bio, Inc. (GRI)

GRI Bio, Inc. (GRI): revenue, margins and EPS from its SEC filings, and Graham's reads as they come out.

Reads

• GRI Bio warns of substantial doubt about its ability to continue as a going concern due to ongoing losses and clinical funding needs. Dodd · GRI

From its filings

• Quarter ending 2022-03-31: revenue $0 · EPS -11.62 · filed 2022-05-09
• Quarter ending 2021-12-31: revenue $0 · EPS -0.44 · filed 2022-02-14
• Quarter ending 2021-09-30: revenue $0 · EPS -0.18 · filed 2021-11-12
• Quarter ending 2021-06-30: revenue $0 · EPS -0.34 · filed 2021-08-10
• Quarter ending 2021-03-31: revenue $0 (-100.0% vs a year earlier) · EPS -0.46 · filed 2022-05-09
• Quarter ending 2020-12-31: revenue $0 · filed 2022-02-14
• Quarter ending 2020-09-30: revenue $0 · EPS -0.23 · filed 2021-11-12
• Quarter ending 2020-06-30: revenue $0 · EPS -0.25 · filed 2021-08-10

Source: SEC EDGAR, 10-Q/10-K, as filed.